Pipelines Are Full

Amgen is one step closer to gaining FDA approval for its osteoporosis drug, denosumab, also known as Prolia. If approved, sales of the drug could mean billions of dollars in revenue for the company. And local biotech startups are making progress bringing their own innovations to market. Over the past couple years, two firms have been acquired, one commercialized its technology, and another secured additional rounds of venture capital. But the indsutry continues to struggle with sluggish sales and lack of access to capital. The future growth of the Valley’s biotech sector remains a question mark. Special Report featured in this edition.